Breast Cancer | Specialty

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Lackluster T-DM1 Results Surprise Perez

December 22nd 2014

Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings

HCI Connects Precision Medicine With Patient-Centered Care

December 19th 2014

Latest News & Insight: December 19, 2014

December 19th 2014

Frontline T-DM1 Results Disappointing in Phase III MARIANNE Trial

December 19th 2014

Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

December 19th 2014

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

December 17th 2014

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

Dr. Chlebowski on How Weight Loss Improves TNBC Survival

December 16th 2014

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

Gene Test Predicts DCIS Recurrence Risk

December 12th 2014

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk

Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention

December 12th 2014

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1

December 12th 2014

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer

Upfront Fulvestrant Improves Survival Over Anastrozole in HR-Positive MBC

December 12th 2014

Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer

Dr. Nanda On Pembrolizumab Potential for TNBC

December 12th 2014

Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of Chicago, discusses the potential of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer (TNBC). A recent small-scale trial showed treatment response for 18.5% of patients with PD-L1 positive TNBC.

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype

December 12th 2014

Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen

December 11th 2014

Chemo Adds No Benefit to Bisphosphonate In Older Breast Cancer Patients

December 11th 2014

Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.

Tamoxifen's Sustained Power to Prevent Breast Cancer in High-Risk Women Confirmed

December 11th 2014

Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.

Ovarian Suppression Emerges as "Practice-Changing" Option for Younger, Premenopausal Breast Cancer Patients

December 11th 2014

Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

TNBC Subtype Responds Favorably to Neoadjuvant Bevacizumab

December 11th 2014

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.